In a secondary analysis of HELIOS-B (654 patients with ATTR cardiomyopathy), vutrisiran's effect vs placebo on death and recurrent CV events did not differ significantly by baseline tafamidis use (RR 0.79, 95% CI 0.51-1.21 with vs 0.67, 0.49-0.93 without; P interaction 0.55).
Secondary analysisn = 654
Hamatani et al. Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B